Please wait while the formulary information is being retrieved.
POLIVY (polatuzumab vedotin-piiq)
- Diffuse large b-cell lymphoma
140 mg intravenous solution
- Infuse 1.8 mg/kg over 90 minute(s) by intravenous route on day 1 of a21 day cycle for 6 cycles
Diffuse large b-cell lymphoma
- Infuse 1.8 mg/kg over 90 minute(s) by intravenous route on day 1 of a21 day cycle for 6 cycles
- Infuse 1.8 mg/kg over 30 minute(s) by intravenous route on day 1 of a21 day cycle for 6 cycles
- Infuse 1.4 mg/kg over 90 minute(s) by intravenous route on day 1 of a21 day cycle for 6 cycles
- Infuse 1.4 mg/kg over 30 minute(s) by intravenous route on day 1 of a21 day cycle for 6 cycles
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Progressive multifocal leukoencephalopathy
Contraindicated
- Peripheral neuropathy
- Pregnancy
Severe
Moderate
- Anemia
- Disease of liver
- Neutropenic disorder
- Severe infection
- Thrombocytopenic disorder
POLIVY (polatuzumab vedotin-piiq)
- Diffuse large b-cell lymphoma
- Anemia
- Chemotherapy-induced hyperuricemia
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Anorexia
- Chills
- Diarrhea
- Dyspnea
- Fatigue
- Fever
- Flushing
- Hypotension
- Peripheral neuropathy
More Frequent
Severe
Less Severe
- Cytomegalovirus disease
- Elevated serum lipase
- Hepatocellular damage
- Herpes simplex infection
- Hyperbilirubinemia
- Hypoalbuminemia
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Infection
- Interstitial pneumonitis
- Lymphopenia
- Pancytopenia
- Arthralgias
- Blurred vision
- Dizziness
- Upper respiratory infection
- Urticaria
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Progressive multifocal leukoencephalopathy
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Polatuzumab vedotin-piiq
Safety and effectiveness have not been established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness have not been established in pediatric patients.
Polatuzumab Vedotin-piiq
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible
Contraindicated
Polatuzumab Vedotin-piiq
Manufacturer does not recommend during tx and for 2 mo after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Manufacturer does not recommend during tx and for 2 mo after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Polatuzumab Vedotin-piiq
General-Patients older than 64 years showed higher incidence of serious ADRs (neutropenia, thrombocytopenia, anemia, hypokalemia, pneumonia).
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Diffuse large b-cell lymphoma | |
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
Formulary Reference Tool